Journey of a patient with chronic thromboembolic pulmonary hypertension

A woman aged 68 years was admitted to our hospital due to progressive dyspnea in March 2008. She presented mild bilateral leg edema at physical examination. The ECG showed acute right ventricular strain (SI/QIII) and sinus tachycardia (heart rate = 120 beats/min). Blood tests evidenced elevated serum D-dimer (2.59 mg/L, that is, fivefold increase). Computed tomography (CT) revealed extensive bilateral thrombi in proximal and peripheral pulmonary arteries plus RV dilation and hypertrophy (Figure 1A,B,C). Pulmonary function tests indicated GOLD II chronic obstructive pulmonary disease (COPD). Arterial blood gas analysis suggested hypocapnia and hypoxemia (pCO₂ 30 mmHg; PO₂ 64 mmHg; O₂ saturation 94%). Initial transthoracic echocardiography (TTE; Table 1) showed a significantly dilated RV with D-shaped left ventricle (LV) and a dilated right atrium (RA). LV and left atrium dimensions as well as LV ejection fraction were normal. Doppler-derived maximal systolic pulmonary artery pressure (SPAP) was 69 mmHg (maximum trans-tricuspid pressure gradient of 59 mmHg + estimated RA pressure of 10 mmHg). Diagnosis of CTEPH was established by above examinations and right heart catheterization examination. Other causes of PH were excluded. Initial therapy consisted of sildenafil (3 × 20 mg/day), oral anticoagulation, and diuretics. Therapy was sequentially escalated towards triple therapy including inhaled iloprost (6 × 2.5 μg/day) and endothelin receptor blockade with ambrisentan (1 × 10 mg/day). The patient repeatedly refused evaluation for pulmonary endarterectomy (PEA) and remained clinically stable on WHO level III for 4 years. The N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) levels also remained stable initially, but increased during long-term follow-up (from 2,400 to 14,300 pg/mL; Figure 2). The patient presented with decompensated right heart failure in October 2012 and was evaluated for PEA and heart/lung transplantation; however, the evaluation results were negative. After a stable period of several months under standard medication, the patient presented again with decompensated right heart failure in August 2013 and died in hospital due to cardiogenic shock.

Serial TTE (Figure 3) revealed a constant elevation of Doppler-derived SPAP with the highest value of 86 mmHg between March 2008 and April 2012. Right heart catheterization showed correspondingly high mean pulmonary arterial pressure of 38 to 45 mmHg at this period (Table 1). Of note, Doppler-derived SPAP gradually decreased over the last two examinations. Reduced tricuspid annular plane systolic excursion (TAPSE; Figure 4, left) and RV fractional area (FAC) were additionally seen throughout the follow-up. Two-dimensional speckle tracking imaging (STI) revealed severely impaired RV longitudinal function (global longitudinal strain = −11%) with predominantly compromised function at the apex (Figure 3, right). Additionally, tricuspid regurgitation (TR) continuous-wave Doppler demonstrated a nominally “normal” peak pressure gradient (19 mmHg) with a late peaking velocity spectrum at the final examination. Interestingly, a normal tricuspid pressure gradient with a normal early peaking velocity spectrum was shown by Doppler echocardiography performed in 2007 before the clinical event of pulmonary thromboembolism (Figure 3).

NT-proBNP levels, 6-min walk distance (6MWD), and invasive hemodynamic monitoring suggested that severe PH existed during the whole disease journey. Extremely enlarged RV and RA, dilated main PA diameter, and decreased cardiac output, as well as increased pulmonary vascular resistance also provided circumstantial evidence on progressive worsening in both RV volume and pressure overload in this patient. However, significantly elevated tricuspid pressure gradient in the early phase of CTEPH normalized at the late phase of this patient’s clinical journey. The potential reasons for pseudo-normalization of SPAP during development in this patient remain an issue of speculation. This decline of the pressure gradient is not due to improvement of tricuspid regurgitation but rather a feature of progressive right ventricular dysfunction, as indicated by a sustained reduction in TAPSE, RV FAC, and correspondingly reduced RV longitudinal strain in STI (Figure 3). Previous experimental study on chronic RV pressure overload model proved that RV systolic function is preserved, but diastolic function is impaired. To compensate, RA contractility increases to maintain filling stiffened ventricle, and the atrium acts as a reservoir than a conduit [6]. As time passes, RA pressure comes to be further increased due to the exhaustion of RA contractility. When the increased degree in the RA pressure is more than in the RV pressure, the pressure difference between RV and RA (tricuspid pressure gradient) will be reduced. Thus, we speculate that pseudo-normalization of the pressure gradient should not be interpreted as a positive treatment response but rather as an ominous sign of advancing right heart failure owing to an exhaustion of RV and RA contractile function. The shape of the velocity spectrum is another important sign in this context as the late-peaking velocity trace might be related to RV contractile dysfunction.

Additionally, we observed the discrepancy between echocardiographic-derived SPAP (reduced) and right heart catheterization measured pulmonary artery systolic pressure (increased) during the late course of PH in this patient. The underlying reason might be that echocardiographic-derived SPAP reflects the pressure gradient between RV and RA, which is low due to increased RA pressure in this patient at late disease phase. While invasive right heart catheterization-measured SPAP presents the real increased pressure situation at pulmonary artery.

In comparison with tricuspid pressure gradient, some clinical indices and other echocardiographic parameters might be additionally useful for predicting the outcome in this case. When retrospectively reviewing the full journey of this patient, sustained elevated NT-proBNP levels and a significantly low 6MWD were observed. Previous studies showed that BNP and NT-proBNP correlated well with RV function and prognosis in several forms of pulmonary hypertension [7-9]. The 6MWD has been widely used for measuring the response to therapeutic interventions for pulmonary and cardiac disease [8]. Our observation also demonstrated the value of monitoring 6MWD for evaluating PH disease progression. Therefore, monitoring these clinical indices during follow-up might be helpful for predicting the adverse outcome in patients with CTEPH besides standard echocardiographic parameters including SPAP, TAPSE, RV FAC, and STI.

The study was approved by Local Ethics Committee at the University of Würzburg and conducted in accordance to the Declaration of Helsinki.

Written informed consent was obtained from the patient’s guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.